beta

ADRO

Aduro Biotech Inc.

Adro

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-30-2018 08-01-2018 05-02-2018 03-01-2018 10-31-2017 08-02-2017 05-02-2017
Actual EPS -0.29 -0.31 -0.28 -0.35 -0.33 -0.27 -0.32
Consensus EPS -0.31 -0.33 -0.3 -0.36 -0.33 -0.36 -0.36
Estimated EPS -0.31 -0.33 -0.3 -0.36 -0.33 -0.36 -0.36
Number of Estimates 5 4 5 5 4 4 4
EPS Surprise $0.02 $0.02 $0.02 $0.01 $0.09 $0.04

Stats

Summary

Aduro Biotech Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies that transform the treatment of different diseases.

Market Cap: 522 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.aduro.com

Shares Outstanding: 77.3 Million

Float: 76.2 Million

Dividend: 0.0 (0.0%)

Beta: 2.994359

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 6.57 Million

Ethical Flags

Animal testing

Longest drawdown: 911 trading days

From: 2015-04-20 To: 2018-12-07

Lowest Point:

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-04 12:56:59:000

More news on: Safe-T Group Ltd Sponsored ADR, American Electric Technologies, Inc., Twist Bioscience Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-04 12:56:59:000

More news on: Safe-T Group Ltd Sponsored ADR, American Electric Technologies, Inc., Twist Bioscience Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-04 12:56:59:000

More news on: Safe-T Group Ltd Sponsored ADR, American Electric Technologies, Inc., Twist Bioscience Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2018-12-04 12:56:59:000

More news on: Safe-T Group Ltd Sponsored ADR, American Electric Technologies, Inc., Twist Bioscience Corporation, Stocks on the move, , Read more … read more...

Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%

via: SeekingAlpha at 2018-11-09 10:54:27:000

Aduro BioTech ( ADRO -10.7% ) is down on below-average volume following its announcement of Phase 1 data on its STING pathway activator ADU-S100. The results are being presented at the SITC annual meeting in Washington, DC. More news on: Aduro Biotech, Merck & Co Inc., Healthcare s… read more...

Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%

via: SeekingAlpha at 2018-11-09 10:54:27:000

Aduro BioTech ( ADRO -10.7% ) is down on below-average volume following its announcement of Phase 1 data on its STING pathway activator ADU-S100. The results are being presented at the SITC annual meeting in Washington, DC. More news on: Aduro Biotech, Merck & Co Inc., Healthcare s… read more...

Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%

via: SeekingAlpha at 2018-11-09 10:54:27:000

Aduro BioTech ( ADRO -10.7% ) is down on below-average volume following its announcement of Phase 1 data on its STING pathway activator ADU-S100. The results are being presented at the SITC annual meeting in Washington, DC. More news on: Aduro Biotech, Merck & Co Inc., Healthcare s… read more...

Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%

via: SeekingAlpha at 2018-11-09 10:54:27:000

Aduro BioTech ( ADRO -10.7% ) is down on below-average volume following its announcement of Phase 1 data on its STING pathway activator ADU-S100. The results are being presented at the SITC annual meeting in Washington, DC. More news on: Aduro Biotech, Merck & Co Inc., Healthcare s… read more...

Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%

via: SeekingAlpha at 2018-11-09 10:54:27:000

Aduro BioTech ( ADRO -10.7% ) is down on below-average volume following its announcement of Phase 1 data on its STING pathway activator ADU-S100. The results are being presented at the SITC annual meeting in Washington, DC. More news on: Aduro Biotech, Merck & Co Inc., Healthcare s… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Aduro Biotech beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-10-30 16:39:31:000

Aduro Biotech (NASDAQ: ADRO ): Q3 GAAP EPS of -$0.29 beats by $0.02 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aduro Biotech beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-10-30 16:39:31:000

Aduro Biotech (NASDAQ: ADRO ): Q3 GAAP EPS of -$0.29 beats by $0.02 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aduro Biotech beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-10-30 16:39:31:000

Aduro Biotech (NASDAQ: ADRO ): Q3 GAAP EPS of -$0.29 beats by $0.02 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Shipping and Biotech top list of midday movers (10/22/2018)

via: SeekingAlpha at 2018-10-22 12:49:47:000

Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo… read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO

via: SeekingAlpha at 2018-10-22 09:20:58:000

ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Merck's tepid STING data pressures Aduro Biotech, down 24% premarket

via: SeekingAlpha at 2018-10-22 07:33:58:000

Thinly traded small cap Aduro Biotech (NASDAQ: ADRO ) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with soli… read more...

Merck's tepid STING data pressures Aduro Biotech, down 24% premarket

via: SeekingAlpha at 2018-10-22 07:33:58:000

Thinly traded small cap Aduro Biotech (NASDAQ: ADRO ) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with soli… read more...

Merck's tepid STING data pressures Aduro Biotech, down 24% premarket

via: SeekingAlpha at 2018-10-22 07:33:58:000

Thinly traded small cap Aduro Biotech (NASDAQ: ADRO ) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with soli… read more...

Aduro Tanks On J&J Partnership Termination Surprise, But Others Remain In Place

via: SeekingAlpha at 2018-10-09 11:12:00:000

Recently, it was noted that Johnson & Johnson ( JNJ ) had pulled out of its deal with Aduro Biotech ( ADRO ). This is not good news for Aduro, but at the same time, I don't believe it will cripple it. Sure, it does lose out on massive amounts of milestone payments. However, there is an… read more...

Aduro Tanks On J&J Partnership Termination Surprise, But Others Remain In Place

via: SeekingAlpha at 2018-10-09 11:12:00:000

Recently, it was noted that Johnson & Johnson ( JNJ ) had pulled out of its deal with Aduro Biotech ( ADRO ). This is not good news for Aduro, but at the same time, I don't believe it will cripple it. Sure, it does lose out on massive amounts of milestone payments. However, there is an… read more...

Aduro Tanks On J&J Partnership Termination Surprise, But Others Remain In Place

via: SeekingAlpha at 2018-10-09 11:12:00:000

Recently, it was noted that Johnson & Johnson ( JNJ ) had pulled out of its deal with Aduro Biotech ( ADRO ). This is not good news for Aduro, but at the same time, I don't believe it will cripple it. Sure, it does lose out on massive amounts of milestone payments. However, there is an… read more...

Janssen Drops Aduro, Too. How Is That Investment Thesis Shaping Up?

via: SeekingAlpha at 2018-10-04 09:00:42:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Recently, one of the biggest p… read more...

Janssen Drops Aduro, Too. How Is That Investment Thesis Shaping Up?

via: SeekingAlpha at 2018-10-04 09:00:42:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Recently, one of the biggest p… read more...

Janssen Drops Aduro, Too. How Is That Investment Thesis Shaping Up?

via: SeekingAlpha at 2018-10-04 09:00:42:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Recently, one of the biggest p… read more...

Midday Gainers / Losers (10/02/2018)

via: SeekingAlpha at 2018-10-02 12:44:16:000

Gainers: OGEN +92% . DTEA +62% . IGC +58% . TRPX +49% . IMTE +43% . SLS +22% . SYN +20% . FTFT +19% . ATRS +19% . INO +18% . More news on: Oragenics, Inc., DAVIDs TEA, India Globalization Capital, Inc, , Stocks on the move, Top stock market news, R… read more...

Midday Gainers / Losers (10/02/2018)

via: SeekingAlpha at 2018-10-02 12:44:16:000

Gainers: OGEN +92% . DTEA +62% . IGC +58% . TRPX +49% . IMTE +43% . SLS +22% . SYN +20% . FTFT +19% . ATRS +19% . INO +18% . More news on: Oragenics, Inc., DAVIDs TEA, India Globalization Capital, Inc, , Stocks on the move, Top stock market news, R… read more...

Janssen bails on developing Aduro's Listeria strains

via: SeekingAlpha at 2018-10-01 16:23:49:000

Aduro Biotech (NASDAQ: ADRO ) reports that licensee Janssen Biotech (NYSE: JNJ ) has notified it that it will terminate its exclusive global license agreement to develop treatments containing attenuated Listeria strains ADU-214, ADU-741 and GVAX Prostate for all indications. More news … read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-09-01 13:03:24:000

Breakout Forecast Selections for Week 36: Market conditions have generated a strong increase in positive breakout momentum and a decline negative momentum this week. The positive momentum gauge continues higher to 65 up from a value of 51 at the end of last week. The yellow positive mome… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Your Daily Pharma Scoop: Mallinckrodt Stumbles, AbbVie Phase 3 Positive, Sierra Makes An Acquisition

via: SeekingAlpha at 2018-08-24 09:23:50:000

Stocks in News: MNK, ABBV FDA rejects Mallinckrodt's stannsoporfin marketing application; shares down 3% premarket Discussion: Mallinckrodt ( MNK ) received a CRL on its marketing application of stannsoporfin for the treatment of severe jaundice in neonatals at risk. The CRL w… read more...

Midday Gainers / Losers (08/17/2018)

via: SeekingAlpha at 2018-08-17 12:45:10:000

Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO… read more...

Midday Gainers / Losers (08/17/2018)

via: SeekingAlpha at 2018-08-17 12:45:10:000

Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO… read more...

Midday Gainers / Losers (08/17/2018)

via: SeekingAlpha at 2018-08-17 12:45:10:000

Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO… read more...

Midday Gainers / Losers (08/17/2018)

via: SeekingAlpha at 2018-08-17 12:45:10:000

Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO… read more...

Midday Gainers / Losers (08/17/2018)

via: SeekingAlpha at 2018-08-17 12:45:10:000

Gainers: TIK +56% . ZOES +34% . IZEA +28% . CNET +19% . CRMT +18% . YRD +15% . GEMP +13% . PPDF +13% . JWN +12% . ADRO +11% . Losers: ZN -27% . USEG -17% . BOXL -16% . ATGE -15% . DXR -14% . ATAC -14% . AMRS -13% . JMU -14% . ELO… read more...

Aduro Biotech beats by $0.01, misses on revenue

via: SeekingAlpha at 2018-08-01 16:49:43:000

Aduro Biotech (NASDAQ: ADRO ): Q2 EPS of -$0.31 beats by $0.01 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aduro Biotech beats by $0.01, misses on revenue

via: SeekingAlpha at 2018-08-01 16:49:43:000

Aduro Biotech (NASDAQ: ADRO ): Q2 EPS of -$0.31 beats by $0.01 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aduro Biotech beats by $0.01, misses on revenue

via: SeekingAlpha at 2018-08-01 16:49:43:000

Aduro Biotech (NASDAQ: ADRO ): Q2 EPS of -$0.31 beats by $0.01 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics prices IPO in range at $16/share

via: SeekingAlpha at 2018-06-26 18:59:19:000

Neon Therapeutics ( NTGN ) has priced its initial public offering at $16, in the middle of its marketed range, IPO IPO Boutique reports. More news on: Neon Therapeutics, Aduro Biotech, Advaxis Inc., Healthcare stocks news, IPOs, Read more … read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

Neon Therapeutics Looks To Tap Into An Exciting Area Of Cancer Therapy. What Are The Prospects?

via: SeekingAlpha at 2018-06-25 07:54:20:000

Author's note: Subscribers to the Total Pharma Tracker received more insights and access to exclusive discussion on the prospects of Neon Therapeutics. In 2018, the biggest emerging story in cancer medicine that's just under the radar is the targeting of neoantigens. And the company… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

via: SeekingAlpha at 2018-06-11 01:52:40:000

Analysis Focus: ADRO Aduro Biotech Inc. ( ADRO ) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and… read more...

Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

via: SeekingAlpha at 2018-06-11 01:52:40:000

Analysis Focus: ADRO Aduro Biotech Inc. ( ADRO ) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and… read more...

Your Daily Pharma Scoop: Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips

via: SeekingAlpha at 2018-06-11 01:52:40:000

Analysis Focus: ADRO Aduro Biotech Inc. ( ADRO ) is a smallcap with a market capitalization of $533.397M. The company develops immunotherapy drugs, focuses on development of therapies that treat challenging diseases. The Berkeley, CA based company was founded as Oncologic, Inc. in 2000 and… read more...

Aduro Bio announces launch of early-stage study of ADU-214 in lung cancer

via: SeekingAlpha at 2018-06-07 16:20:22:000

Aduro Biotech (NASDAQ: ADRO ) announces that licensee Janssen Biotech (NYSE: JNJ ) has initiated a Phase 1b clinical trial assessing ADU-214, combined with Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab), in patients with advanced/metastatic non-small cell lung cancer, specificall… read more...

Aduro Bio announces launch of early-stage study of ADU-214 in lung cancer

via: SeekingAlpha at 2018-06-07 16:20:22:000

Aduro Biotech (NASDAQ: ADRO ) announces that licensee Janssen Biotech (NYSE: JNJ ) has initiated a Phase 1b clinical trial assessing ADU-214, combined with Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab), in patients with advanced/metastatic non-small cell lung cancer, specificall… read more...

Aduro Bio announces launch of early-stage study of ADU-214 in lung cancer

via: SeekingAlpha at 2018-06-07 16:20:22:000

Aduro Biotech (NASDAQ: ADRO ) announces that licensee Janssen Biotech (NYSE: JNJ ) has initiated a Phase 1b clinical trial assessing ADU-214, combined with Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab), in patients with advanced/metastatic non-small cell lung cancer, specificall… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Aduro Biotech (ADRO) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-05-18 14:44:16:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Celldex Trying To Regroup With Its Early-Stage Assets

via: SeekingAlpha at 2018-05-11 11:59:48:000

It was clear back in April that Celldex Therapeutics ( CLDX ) would be restructuring and realigning its priorities after the failure of its Phase III METRIC study of glembatumumab ("glemba") in triple-negative breast cancer, and after the first quarter earnings report, investors have a clear… read more...

Celldex Trying To Regroup With Its Early-Stage Assets

via: SeekingAlpha at 2018-05-11 11:59:48:000

It was clear back in April that Celldex Therapeutics ( CLDX ) would be restructuring and realigning its priorities after the failure of its Phase III METRIC study of glembatumumab ("glemba") in triple-negative breast cancer, and after the first quarter earnings report, investors have a clear… read more...

Aduro Biotech beats by $0.07, beats on revenue

via: SeekingAlpha at 2018-05-02 16:58:10:000

Aduro Biotech (NASDAQ: ADRO ): Q1 EPS of -$0.28 beats by $0.07 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Aduro Biotech beats by $0.07, beats on revenue

via: SeekingAlpha at 2018-05-02 16:58:10:000

Aduro Biotech (NASDAQ: ADRO ): Q1 EPS of -$0.28 beats by $0.07 . More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, Read more … read more...

3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close

via: SeekingAlpha at 2018-04-21 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, April 20: AstraZeneca Re-Enters The Big Leagues, Aduro Looks Ahead, Lilly Looks Close

via: SeekingAlpha at 2018-04-21 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Aduro Biotech (ADRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow

via: SeekingAlpha at 2018-04-10 12:20:58:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Aduro Biotech (ADRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow

via: SeekingAlpha at 2018-04-10 12:20:58:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-04-06 07:14:53:000

Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-04-06 07:14:53:000

Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare (continued #1)

via: SeekingAlpha at 2018-03-16 10:26:29:000

Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR );Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS… read more...

Key events next week - healthcare (continued #1)

via: SeekingAlpha at 2018-03-16 10:26:29:000

Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR );Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS… read more...

Aduro Biotech (ADRO) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:32:34:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Aduro Biotech (ADRO) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:32:34:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Your Daily Pharma Scoop: Genocea Surges, Gilead's Biktarvy, GlaxoSmithKline's Vaccine Succeeds In Late-Stage Study

via: SeekingAlpha at 2018-03-07 08:00:00:000

Analysis of top Seeking Alpha coverage: Genocea Biosciences Today, we will discuss Genocea Biosciences (GNCA), which is up sharply after a bullish note from Cantor Fitzgerald. In early trading, GNCA shares were up nearly 10%, offsetting some of the losses the company has incurred in 2018. Ye… read more...

Your Daily Pharma Scoop: Genocea Surges, Gilead's Biktarvy, GlaxoSmithKline's Vaccine Succeeds In Late-Stage Study

via: SeekingAlpha at 2018-03-07 08:00:00:000

Analysis of top Seeking Alpha coverage: Genocea Biosciences Today, we will discuss Genocea Biosciences (GNCA), which is up sharply after a bullish note from Cantor Fitzgerald. In early trading, GNCA shares were up nearly 10%, offsetting some of the losses the company has incurred in 2018. Ye… read more...

Aduro Biotech beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-03-01 16:04:09:000

Aduro Biotech (NASDAQ: ADRO ): Q4 EPS of -$0.34 beats by $0.02 . Revenue of $3.76M (-3.1% Y/Y) misses by $0.45M . Press Release More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, read more...

Aduro Biotech beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-03-01 16:04:09:000

Aduro Biotech (NASDAQ: ADRO ): Q4 EPS of -$0.34 beats by $0.02 . Revenue of $3.76M (-3.1% Y/Y) misses by $0.45M . Press Release More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-22 08:46:38:000

Aduro Biotech (NASDAQ: ADRO ) initiated with Overweight rating and $15 (146% upside) price target at Cantor Fitzgerald. More news on: Aduro Biotech, Loxo Oncology, Asterias Biotherapeutics, Inc., Healthcare stocks news, Read more … read more...

Midday Gainers / Losers (1/24/2018)

via: SeekingAlpha at 2018-01-24 12:46:54:000

Gainers: OPGN +58% . ACHV +51% . OHGI +29% . HTM +27% . SRT +20% . CERS +18% . RFIL +17% . CARA +17% . ANTH +16% . GWW +16% . More news on: OpGen, Achieve Life Sciences, Inc., One Horizon Group, Inc., Stocks on the move, Read more … read more...

Aduro Biotech (ADRO) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-12 11:37:32:000

The following slide deck was published by Aduro Biotech in conjunction with this Read more … read more...

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

via: SeekingAlpha at 2017-12-21 09:42:09:000

Content Analysis of coverage: AEZS Stocks in the news: Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Catalyst Rundown Analysis of top Seeking Alpha coverage: AEterna Zentaris Today we will foc… read more...

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

via: SeekingAlpha at 2017-12-21 02:41:58:000

Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...

Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering

via: SeekingAlpha at 2017-12-19 08:04:09:000

Content Analysis of coverage: RARE Stocks in the news: REGN, MDGL Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Subscriber Questions & Answers (for TPT Subscribers only) Catalyst Rundown (for… read more...

Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement

via: SeekingAlpha at 2017-12-15 03:35:17:000

Content Analysis of coverage: CNAT Stocks in the news: TEVA, BMY Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & Answers… read more...

Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy

via: SeekingAlpha at 2017-12-14 03:17:04:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Abbvie and Roche Put Out Amazing Phase 3 Leukemia Data News: Recently, Abbvie ( ABBV ) and Roche ( RHHBY ) announced positive phase 3 data in pat… read more...

3 Things In Biotech You Should Learn Today: December 13, 2017

via: SeekingAlpha at 2017-12-13 08:01:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AbbVie spikes the ball at ASH 2017 Company: AbbVie ( ABBV ) and Roche ( RHHBY ) Therap… read more...

3 Things In Biotech You Should Learn Today: November 5, 2017

via: SeekingAlpha at 2017-11-05 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Ionis takes its swing in Europe Company: Ionis Pharmaceuticals ( IONS ) Therapy: Inot… read more...

Aduro Biotech beats by $0.03, misses on revenue

via: SeekingAlpha at 2017-10-31 16:15:23:000

Aduro Biotech (NASDAQ: ADRO ): Q3 EPS of -$0.33 beats by $0.03 . Revenue of $3.79M (flat Y/Y) misses by $2.34M . Press Release More news on: Aduro Biotech, Earnings news and commentary, Healthcare stocks news, read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX